Suchergebnisse - "Renouf, Daniel J"

PubPharm (173)

1

Exploration of Germline Correlates and Risk of Immune-Related Adverse Events in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors

enthalten in: Current oncology (Toronto, Ont.) | 2024

von Titmuss, E. | Yu, I. | Pleasance, E. | +9

2

Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature : An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Nicolle, R. | Bachet, J. | Harlé, A. | +18

3

Nutrient scavenging-fueled growth in pancreatic cancer depends on caveolae-mediated endocytosis under nutrient-deprived conditions

enthalten in: Science advances | 2024

von Wolfe, A. | Cui, T. | Baie, S. | +17

4

Mappingin silicogenetic networks of theKMT2Dtumour suppressor gene to uncover novel functional associations and cancer cell vulnerabilities

enthalten in: bioRxiv.org | 2024

von Takemon, Y. | Pleasance, E. | Gagliardi, A. | +16

5

Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment

enthalten in: Cancer immunology, immunotherapy : CII | 2024

von Baginska, J. | Nau, A. | Gomez Diaz, I. | +19

6

Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment

enthalten in: Cancer immunology immunotherapy | 2024

von Baginska, J. | Nau, A. | Gomez Diaz, I. | +19

7

Loss of ATG4B and ATG4A results in two-stage cell cycle defects in pancreatic ductal adenocarcinoma cells

enthalten in: Journal of cell science | 2023

von Sathiyaseelan, P. | Chittaranjan, S. | Kalloger, S. | +14

8

Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors

enthalten in: Investigational new drugs | 2023

von Stathis, A. | Tolcher, A. | Wang, J. | +7

9

Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors

enthalten in: Investigational new drugs | 2023

von Stathis, A. | Tolcher, A. | Wang, J. | +7

10

Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors

enthalten in: Investigational new drugs | 2023

von Stathis, A. | Tolcher, A. | Wang, J. | +7

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[18]